SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Thomas A. Zelniker(Thrombolysis in Myocardial Infarction Study Group), Stephen D. Wiviott(Thrombolysis in Myocardial Infarction Study Group), Itamar Raz(Hadassah Medical Center), KyungAh Im(Thrombolysis in Myocardial Infarction Study Group), Erica L. Goodrich(Brigham and Women's Hospital), Marc P. Bonaca(Thrombolysis in Myocardial Infarction Study Group), Ofri Mosenzon(Hebrew University of Jerusalem), Eri Kato(Kyoto University), Avivit Cahn(Hebrew University of Jerusalem), Remo H.M. Furtado(Thrombolysis in Myocardial Infarction Study Group), Deepak L. Bhatt(Thrombolysis in Myocardial Infarction Study Group), Lawrence A. Leiter(St. Michael's Hospital), Darren K. McGuire(The University of Texas Southwestern Medical Center), John Wilding(University of Liverpool), Marc S. Sabatine(Brigham and Women's Hospital)
The Lancet
November 10, 2018
Cited by 2,791

Abstract


Related Papers

No related papers found

Powered by citation graph analysis